ID   MB-1
AC   CVCL_2109
SY   MB1
DR   BioSample; SAMN03473455
DR   cancercelllines; CVCL_2109
DR   Cell_Model_Passport; SIDM01639
DR   DepMap; ACH-001356
DR   DSMZ; ACC-638
DR   DSMZCellDive; ACC-638
DR   Wikidata; Q54904088
RX   PubMed=18616678;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: ~36 hours (PubMed=18616678); ~60-100 hours (DSMZ=ACC-638).
CC   Karyotypic information: Has lost chromosome Y (PubMed=18616678).
CC   Omics: Deep exome analysis.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): DepMap=ACH-001356; DSMZ=ACC-638
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 19
ST   D19S433: 15
ST   D21S11: 31
ST   D2S1338: 20
ST   D3S1358: 14
ST   D5S818: 10
ST   D7S820: 9
ST   D8S1179: 13
ST   FGA: 23
ST   Penta D: 15
ST   Penta E: 13
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 14
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 20
//
RX   PubMed=18616678; DOI=10.1111/j.1349-7006.2008.00882.x;
RA   Stenner F., Liewen H., Zweifel M., Weber A., Tchinda J., Bode B.,
RA   Samaras P., Bauer S., Knuth A., Renner C.;
RT   "Targeted therapeutic approach for an anaplastic thyroid cancer in
RT   vitro and in vivo.";
RL   Cancer Sci. 99:1847-1852(2008).
//